Global Narcolepsy Therapeutics Market Size (2024 - 2029)

The narcolepsy therapeutics market is poised for substantial growth, driven by factors such as the increasing prevalence of narcoleptic disorders, rising stress levels, and a growing geriatric population. The market's expansion is further supported by heightened awareness of treatment options and the approval of new drugs. However, challenges like delayed diagnosis or misdiagnosis could impede market growth. The impact of COVID-19, which led to decreased adoption of therapeutics, has also been significant, particularly in exacerbating symptoms for patients.

Market Size of Global Narcolepsy Therapeutics Industry

Narcolepsy Therapeutics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 9.90 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Narcolepsy Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Narcolepsy Therapeutics Market Analysis

The narcolepsy therapeutics market is anticipated to witness a CAGR of 9.9% during the forecast period (2022-2027).

COVID-19 had a significant impact on the market growth due to decreased adoption of narcolepsy therapeutics during the pandemic. For instance, according to the study titled "The effects of the COVID-19 pandemic on patients with narcolepsy" published in April 2021, during the quarantine, the patients with narcolepsy reported changes in their bedtime and waking-up schedules, suggesting a tendency to circadian misalignment. It also reported that COVID-19 had amplified the symptoms of rare diseases such as narcolepsy in Brazil. Thus, COVID-19 had a pronounced impact on the narcolepsy therapeutics market.

The increasing prevalence of narcoleptic disorders across the world, rising stress levels, a growing geriatric population, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market. For instance, the study titled "Prevalence, incidence, and health care utilization of patients with narcolepsy: a population-representative study" published in January 2022 reported that the early incidence of narcolepsy in Europe is 0.64-1.37 per 100,000. Such a high incidence of disorder leads to the increased adoption of narcolepsy therapies, which is expected to drive the market's growth over the forecast period.

In addition, according to the study titled "Narcolepsy Presentation in Diverse Populations: an Update" published in November 2020, narcolepsy affects 0.87-1.21% of the world's population, specifically narcolepsy type 1 (NT1). The rising prevalence of narcolepsy globally creates the need for narcolepsy therapeutics for the treatment and thus contributes to the growth of the market.

The approval and commercialization of new drugs by market players may also play a crucial role in driving market growth over the coming years. For instance, in March 2021, the United States Food and Drug Administration (FDA) accepted Avadel's New Drug Application (NDA) for FT218, an investigational, once-nightly formulation of sodium oxybate used in the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Thus, owing to the abovementioned factors, the market is expected to project significant growth over the forecast period. However, delayed diagnosis or misdiagnosis may hamper the growth of the narcolepsy therapeutics market.

Narcolepsy Therapeutics Industry Segmentation

As per the scope of the report, narcolepsy is a long-term neurological disorder involving decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that last from seconds to minutes and can occur at any time. Around 70% of people experience episodes of a sudden loss of muscle strength, known as cataplexy, which can also strongly affect the emotional state of patients. The Narcolepsy Therapeutics Market is segmented by Type (Cataplexy and Without Cataplexy), Product (Central Nervous System Stimulants, Sodium Oxybate, and Tricyclic Antidepressants), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type
Narcolepsy with Cataplexy
Narcolepsy without Cataplexy
Secondary Narcolepsy
By Product
Central Nervous System Stimulants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitors
Tricyclic Antidepressants
Other Products
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Narcolepsy Therapeutics Market Size Summary

The narcolepsy therapeutics market is poised for significant growth, driven by factors such as the increasing prevalence of narcoleptic disorders, rising stress levels, and a growing geriatric population. The market is expected to expand due to heightened awareness of treatment options and the approval of new drugs by key players. The COVID-19 pandemic had a notable impact on market growth, as it led to decreased adoption of therapeutics and exacerbated symptoms in some regions. Despite challenges like delayed diagnosis, the market is set to benefit from advancements in central nervous system stimulants, which are crucial for improving wakefulness in patients. The development of novel therapies and regulatory approvals are central to the market's expansion.

North America is anticipated to hold a significant share of the market, supported by high healthcare spending, favorable reimbursement policies, and a strong clinical pipeline. The region's growth is further bolstered by the increasing demand for sleep disorder treatments and the effectiveness of narcolepsy therapies. The market is moderately competitive, with major players engaging in collaborations and acquisitions to drive innovation. Companies such as Avadel Pharmaceuticals, Harmony Biosciences, and Jazz Pharmaceuticals are key contributors to the market's development. The ongoing research and development efforts, along with financial support for neurological research, are expected to sustain the market's growth trajectory in the coming years.

Explore More

Global Narcolepsy Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Global Prevalence of Narcolepsy

      2. 1.2.2 Narcolepsy Awareness Programs and Services

      3. 1.2.3 Presence of Reimbursement Policies Regarding Narcolepsy

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Effects and Risks Related to Narcolepsy Drugs

      2. 1.3.2 Delayed Diagnosis or Misdiagnosis

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type

      1. 2.1.1 Narcolepsy with Cataplexy

      2. 2.1.2 Narcolepsy without Cataplexy

      3. 2.1.3 Secondary Narcolepsy

    2. 2.2 By Product

      1. 2.2.1 Central Nervous System Stimulants

      2. 2.2.2 Sodium Oxybate

      3. 2.2.3 Selective Serotonin Reuptake Inhibitors

      4. 2.2.4 Tricyclic Antidepressants

      5. 2.2.5 Other Products

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Narcolepsy Therapeutics Market Size FAQs

The Global Narcolepsy Therapeutics Market is projected to register a CAGR of 9.90% during the forecast period (2024-2029)

Jazz Pharmaceuticals plc , Takeda Pharmaceutical Company , Teva Pharmaceuticals USA, Inc., Shionogi Inc and Novartis International AG are the major companies operating in the Global Narcolepsy Therapeutics Market.

Narcolepsy Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)